James Bailen
Urology · Jeffersonville, INNPI 1639166713
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Johnson & Johnson at 36.1% of the total. Reporting peaked in 2019 at $65,818 and has fallen 99.8% since, to $108 in 2024. Among urology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 546 payments — averaging $262.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$52K
- Astellas Pharma US Inc$45K
- Bayer$25K
- AstraZeneca$8K
- Dendreon Pharmaceuticals LLC$4K
- Pfizer$3K
- plus $7K from 23 others
Across 1,210 payments — averaging $4752.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medivation LLC.$2.8M
- Pfizer$941K
- Janssen Research & Development, LLC$539K
- Bayer$527K
- Dendreon Pharmaceuticals LLC$346K
- AbbVie$182K
- plus $385K from 12 others
What the payments were for
- Consulting fees$35,60025%
- Speaking & faculty fees$84,59559%
- Travel & lodging$10,9368%
- Food & beverage$11,6628%
- Education$3400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 129 | $51,698 |
| Astellas Pharma US Inc | 84 | $44,920 |
| Bayer | 83 | $24,991 |
| AstraZeneca | 12 | $8,422 |
| Dendreon Pharmaceuticals LLC | 117 | $3,634 |
| Pfizer | 24 | $2,760 |
| Janssen Scientific Affairs, LLC | 3 | $2,150 |
| Exelixis Inc. | 1 | $1,470 |
| Medtronic(2 entities) | 10 | $755 |
| Novartis | 15 | $316 |
| Amgen | 14 | $241 |
| AbbVie | 9 | $231 |
| Urogen Pharma, Inc. | 2 | $222 |
| Myovant Sciences Inc. | 8 | $139 |
| Progenics Pharmaceuticals, Inc. | 4 | $136 |
| Teleflex LLC | 2 | $133 |
| Foundation Medicine, Inc. | 1 | $125 |
| Merck | 6 | $114 |
| Boehringer Ingelheim | 1 | $112 |
| Clarus Therapeutics Inc. | 1 | $110 |
| Blue Earth Diagnostics | 4 | $94 |
| Clovis Oncology, Inc. | 3 | $93 |
| Sun Pharmaceutical Industries Inc. | 5 | $81 |
| Ferring Pharmaceuticals Inc. | 3 | $51 |
| Siemens Medical Solutions USA, Inc. | 1 | $39 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Endo Pharmaceuticals Inc. | 1 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $24 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$52,247
- XTANDI$43,284
- Nubeqa$13,948
- LYNPARZA$8,273
- Xofigo$7,201
- Non-Covered$2,224
- PROVENGE$2,221
- Cabometyx$1,470
- TALZENNA$1,110
- INTERSTIM$472
- JATENZO$329
- JELMYTO$133
- Balversa$130
- FOUNDATIONONE$125
- FOUNDATIONONE HEME$125
- FOUNDATIONONE CDX$125
- FOUNDATIONFOCUS$125
- FOUNDATIONONE LIQUID$125
- ELIQUIS$120
- FASENRA$117
How this compares
$143,132 in reported general payments places this provider in the 95th percentile of 272 urology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 15 | $47,011 |
| Prednisone | 14 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $2,150 | $47,01115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 272 urology providers in Indiana.
Other urology in Jeffersonville
- Greg SteinbockJeffersonville$134K
- Ryan MaloneJeffersonville$97K
- William SchmiedJeffersonville$58K
- Barry PechaJeffersonville$50K
- David RosenbaumJeffersonville$39K
- John EiflerJeffersonville$26K
- Ganesh RaoJeffersonville$19K
- Bradley BellJeffersonville$16K
- Aaron BeckerJeffersonville$14K
- Dennis SmithJeffersonville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.